PuraCath Medical Shows Significant Reduction in Causes of Peritonitis in Peritoneal Dialysis International Journal

puracath • March 7, 2017

“Publishing the result of our new research on our UV light-based peritoneal dialysis catheter connection system in PDI is a significant accomplishment for PuraCath team since it signifies approval of the data extracted from our newly designed device by the elite scientific society of peritoneal dialysis,” said Julia Rasooly, PuraCath Medical’s CEO. “We believe our approach towards reducing microbial growth through the use of our inexpensive technology will provide patients on peritoneal dialysis a chemical-free, technique-independent method for reducing bacterial and fungal contamination during peritoneal dialysis exchanges.” In vitro testing demonstrated the effectiveness of the UV light-based peritoneal dialysis catheter connection system in achieving a 4-log reduction of several microorganisms which are known to cause peritonitis in patients on peritoneal dialysis therapy. The mean log reduction of these microorganisms was 4.03 for Candida albicans, 4.73 for Staphylococcus aureus, and 5.29 for Escherichia coli. Here is the link to PuraCath’s article in PDI:  http://www.pdiconnect.com/content/37/1/109.short

In 2016, PuraCath received 510(k) clearance for its FireFly Peritoneal Dialysis Connector Disinfecting System which gave the company permission to market the FireFly device in the U.S. The device is intended for use by patients on peritoneal dialysis therapy as a method of controlling air and touch contamination while performing peritoneal dialysis exchanges.

March 27, 2025
PuraCath Medical TM , a venture-backed startup company focusing on the development of technologies to reduce infections in patients with intravascular catheters, announced today its participation in four prominent clinical conferences in 2025. The company will join healthcare professionals and industry experts to present its latest advancements in UV disinfection technology and its impact on reducing Catheter-Line Associated Bloodstream Infections (CLABSIs). PuraCath Medical will be attending the following clinical conferences: ASPEN 2025 Nutrition Science & Practice Conference ONS 2025 Congress (Oncology Nursing Society) NHIA 2025 Annual Conference (National Home Infusion Association) CVAA 2025 Conference (Canadian Vascular Access Association) At each event, PuraCath Medical will present new data on the effectiveness of its UV disinfection technology, alongside findings from simulation studies conducted with device end users.  “PuraCath Medical is excited to share 99.99% or 4-log disinfection data on its latest Firefly Disinfection Device and believes that it can be the solution to CLABSI reduction in vascular access lines worldwide” said Julia Rasooly, PuraCath Medical’s CEO. For more information on PuraCath Medical’s clinical initiatives and conference schedule, please visit www.puracath.com What is a CLABSI (Catheter-Line Associated Bloodstream Infection)? A CLABSI (Catheter-Line Associated Bloodstream Infection) is a laboratory confirmed bloodstream infection related to a central line such as a central venous catheter, PICC line, midline, etc. CLABSIs are associated with a high-cost burden, accounting for approximately $46,000 per case, due to prolonged hospital stays and increased mortality. More than 250,000 CLABSIs are known to occur annually in the U.S. The most common cause of a CLABSI is due to improper aseptic techniques or lack of compliance to proper aseptic techniques, and improper management of the catheter lines during access. About PuraCath Medical TM PuraCath Medical TM , a Silicon Valley based-company, is dedicated to improving the quality of life of patients by reducing the risk of infections. The Company is utilizing its technology platform, which was spun out of Stanford University’s Biodesign program, to develop novel, easy-to-use devices designed to reduce the risk of infections in patients with catheters in order to decrease infection-related hospitalizations and their associated costs. PuraCath Medical TM has received prestigious small business government grants from the National Institute of Health (NIH), National Institute of Allergy and Infectious Disease (NIAID) with grant ID Numbers R43AI134553 and SB1AI174371 to support these initiatives. Julia Rasooly, PuraCath Medical TM , http://www.puracath.com , julia@puracath.com
October 10, 2024
PuraCath Medical™, a venture-backed startup company focusing on the development of technologies to reduce infections in patients with intravascular catheters, announced today that it has published the result of its research on its ultraviolet (UV) light-based intravascular catheter connection disinfection system in the American Journal of Infection Control (AJIC), a peer-reviewed scientific journal published by Elsevier on behalf of the Association for Professionals in Infection Control and Epidemiology.
October 9, 2024
Central Line-associated Bloodstream Infections (CLABSIs) are deadly bloodstream infections with high mortality and morbidity rates in patients with vascular catheters. In the United States, around 250,000 occur yearly. Of these, about 80,000 occur in intensive care units.
PuraCath Medical Receives 510(k) Clearance for its Needleless Connector for Vascular Access
By puracath August 3, 2021
Device is intended for use primarily by ICU nurses during infusions in patients in a critical care setting. PuraCath Medical™, a venture-backed startup company focusing on the development of technologies to reduce infections in patients with intravascular catheters, announced today that it has received 510(k) clearance for its FireFly™ Needleless Connector from the U.S. Food […]
Why We Aren’t Using UV to Disinfect Everything—Yet
By puracath June 16, 2020
Negative perception and costs pose obstacles to a promising technology As the coronavirus pandemic continues, a technology that has existed for over 100 years is getting renewed attention as a promising disinfection tool. Ultraviolet germicidal radiation, which uses short-wavelength UV rays to kill bacteria and viruses, is already used to disinfect the air, water, and […]
PuraCath UV Device Displays a 99.9999% Disinfection of COVID-19 Virus in 1 Second
By puracath April 27, 2020
PuraCath has been partnered and working with a top tier BSL-3 National Laboratory, which has a premiere high containment infectious disease facilities to test its Firefly UV device for the ICU and hospitals with 2019-nCoV (the COVID-19 virus). The preliminary results show that PuraCath’s device has achieved 99.9999% disinfection with SARS-CoV-2 (the virus that is […]
PuraCath FireflyTM Can Kill Deadly Microorganisms with UV Light, Like SARS CoV-2
By puracath March 19, 2020
President Trump has officially declared a national emergency. A novel coronavirus has been identified in Wuhan City, China and has spread worldwide. It has been named SARS CoV-2 (causing disease COVID-19) by WHO. SARS CoV-2 has officially become a global pandemic by WHO. There have already been over 170,000 confirmed cases to date with an […]
By puracath June 19, 2019
JUNE 18, 2019 PuraCath Medical, a venture-backed medical device company based in Silicon Valley, announced today that it has achieved 99.99% disinfection on its vascular access Firefly disinfection technology system with Candida auris (‘superbug’), Staphylococcus aureus, and Candida albicans. “Achieving greater than 4 log disinfection in these virulent microbes with only one second of UV […]
PuraCath Medical to Present Data on FireFly™ Peritoneal Dialysis Connector Disinfecting System durin
By Larry Yost May 12, 2016
San Francisco, California (May 12, 2016) – Data being presented will support planned introduction of PuraCath Medical’s technology in the European Union. PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it will present data on its next generation version of the FireFly™ […]
PuraCath Medical Presents Data at National Kidney Foundation 2016 Spring Clinical Meetings
By Larry Yost April 28, 2016
Boston, Massachusetts (April 28, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of the FireFly™ Peritoneal Dialysis (PD) Connector Disinfecting System during the National Kidney Foundation’s 2016 Spring Clinical Meetings held […]
More Posts
Share by: